Natera Inc

Latest Results (26.10.2025):

Natera Inc reported strong financial performance in the third quarter of 2023, showcasing significant revenue growth, improved gross margins, and a substantial reduction in cash burn. The company also highlighted advancements in its testing volumes and expanded its clinical pipeline, positioning itself for continued growth in the coming quarters.

Revenue Growth

Natera Inc achieved total revenues of $268.3 million in Q3 2023, marking a 27.4% increase compared to $210.6 million in Q3 2022. Product revenues surged by 32.7%, driven by higher test volumes and improved average selling prices.

Improved Gross Margin

The company delivered a gross margin of 45.1% in Q3 2023, up from 44.7% in the same quarter last year. This improvement was primarily due to increased revenues and ongoing reductions in the cost of goods sold.

Reduction in Cash Burn

Natera Inc successfully reduced its cash burn to approximately $38 million in Q3 2023, a decrease of about 66% compared to Q3 2022. The revised 2023 annual guidance now expects net cash consumption to be between $260 million and $280 million.

Increased Test Volumes

The company processed around 626,000 tests in Q3 2023, a 21% increase from 517,500 tests in Q3 2022. Additionally, oncology tests performed rose by 68%, with Signatera™ clinical units experiencing an 85% growth, marking one of the best quarters on record for this product.

Revised Financial Guidance

Natera Inc raised its 2023 revenue guidance to a range of $1.035 billion to $1.05 billion and adjusted the gross margin outlook to 43% to 44%. This optimistic revision reflects the company's strong performance and strategic initiatives.

Strategic Developments

The company published significant study results, launched new clinical trials, and achieved Medicare coverage for FoundationOne®Tracker in partnership with Foundation Medicine. These advancements reinforce Natera Inc's commitment to expanding its diagnostic and clinical offerings.